Results 11 to 20 of about 114,558 (301)

Preclinical Pharmacokinetics and Safety of Intravenous RTD-1. [PDF]

Antimicrob Agents Chemother, 2022
Severe illness caused by coronavirus disease 2019 (COVID-19) is characterized by an overexuberant inflammatory response resulting in acute respiratory distress syndrome (ARDS) and progressive respiratory failure ( 1 ). Rhesus theta (θ) defensin-1 (RTD-1) is a macrocyclic host defense peptide exhibiting antimicrobial
Park AYJ, Tran DQ, Schaal JB, Wang M, Selsted ME, Beringer PM.   +5 more
europepmc   +3 more sources

Preclinical study the pharmacokinetics of lithium ascorbate

Фармакокинетика и Фармакодинамика, 2016
We have studied the effects of lithium ascorbate on the Wistar male albino rats using a dose of 1 000 mg/kg. The concentration time curves for whole blood and tissue homogenates of 10 different biological substrates were derived (the brain, the frontal ...
A. V. Pronin, O. A. Gromova, I. Ju. Torshin, I. V. Gogoleva, N. Ju. Zhidomorov, I. S. Sardaryan, A. Ju. Volkov   +6 more
doaj   +1 more source

Preclinical pharmacokinetics of benznidazole [PDF]

British Journal of Cancer, 1984
Benznidazole is a lipophilic analogue of misonidazole (MISO) which shows promise as a chemosensitizer for clinical use, particularly in combination with CCNU. We have investigated the detailed pharmacokinetics of benznidazole in mice, dogs and sheep to provide a data base for the estimation of doses required for chemosensitization in man ...
P, Workman, R A, White, M I, Walton, L N, Owen, P R, Twentyman   +4 more
openaire   +2 more sources

Population Pharmacokinetic Modelling to Support the Evaluation of Preclinical Pharmacokinetic Experiments with Lorlatinib [PDF]

Journal of Pharmaceutical Sciences, 2022
The effect of transporters and enzymes on drug pharmacokinetics is increasingly evaluated using genetically modified animals that have these proteins either knocked-out or their human orthologues transgenically expressed. Analysis of pharmacokinetic data obtained in such experiments is typically performed using non-compartmental analysis (NCA), which ...
David Damoiseaux, Wenlong Li, Jos H. Beijnen, Alfred H. Schinkel, Alwin D.R. Huitema, Thomas P.C. Dorlo   +5 more
openaire   +2 more sources

Effect of nivasorexant (ACT‐539313), a selective orexin‐1‐receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects

Pharmacology Research & Perspectives, 2023
Nivasorexant, a selective orexin‐1‐receptor antagonist, has recently been assessed in the treatment of humans with binge‐eating disorder. Herein, the inhibitory potential of nivasorexant on cytochromes P450 (CYPs) 2C9, 2C19, and 3A4 was evaluated.
Benjamin Berger, Priska Kaufmann, Matthias Berse, Alexander Treiber, Nathalie Grignaschi, Jasper Dingemanse   +5 more
doaj   +1 more source

Pharmacokinetics of dimeric dipeptide mimetic of nerve growth factor GC-2 in rats. Part 1. Single and multiple intravascular and extravascular administration. Testing the hypothesis of linearity of pharmacokinetics

Фармакокинетика и Фармакодинамика, 2023
The pharmacokinetics of dimeric dipeptide mimetic of nerve growth factor GC-2 in the rat blood plasma after different routes of administration was studied. The drug was administered at dose of 150 mg/kg by single and repeatedly.
O. Yu. Kravtsova, O. G. Gribakina, G. B. Kolyvanov, A. A. Litvin, P. O. Bochkov, P. Yu. Povarnina, V. P. Zherdev   +6 more
doaj   +1 more source

Preclinical efficacy spectrum and pharmacokinetics of ixabepilone [PDF]

Cancer Chemotherapy and Pharmacology, 2008
Ixabepilone, a semisynthetic analog of natural epothilone B, was developed for use in cancer treatment. This study extends previous findings regarding the efficacy of ixabepilone and its low susceptibility to tumor resistance mechanisms and describes the pharmacokinetics of this new antineoplastic agent.The cytotoxicity of ixabepilone was assessed in ...
Lee, Francis Y. F., Smykla, Richard, Johnston, Kathy, Menard, Krista, McGlinchey, Kelly, Peterson, Russell W., Wiebesiek, Amy, Vite, Gregory, Fairchild, Craig R., Kramer, Robert   +9 more
openaire   +2 more sources

Complex formation of anti‐VEGF‐C with VEGF‐C released during blood coagulation resulted in an artifact in its serum pharmacokinetics

Pharmacology Research & Perspectives, 2020
A phage‐derived human monoclonal antibody against VEGF‐C was developed as a potential anti‐tumor therapeutic and exhibited fast clearance in preclinical species, with notably faster clearance in serum than in plasma.
Daniela Bumbaca Yadav, Arthur E. Reyes II, Priyanka Gupta, Jean‐Michel Vernes, Y. Gloria Meng, Michelle G. Schweiger, Shannon L. Stainton, Germaine Fuh, Paul J. Fielder, Amrita V. Kamath, Ben‐Quan Shen   +10 more
doaj   +1 more source

Absolute bioavailability of a substance with cardioprotective activity (ALM-802) in rats

Фармакокинетика и Фармакодинамика, 2022
The pharmacokinetics of a new potential cardioprotective agent ALM-802 was studied in rats after single intravenous and intragastric administration at doses of 10 and 100 mg/kg, respectively.
G. B. Kolyvanov, P. O. Bochkov, A. A. Litvin, R. V. Shevchenko, A. L. Podolko, V. P. Zherdev   +5 more
doaj   +1 more source

Pharmacokinetics, Safety, and Efficacy of Intravitreal Digoxin in Preclinical Models for Retinoblastoma [PDF]

, 2015
PURPOSE:To assess in vitro cytotoxic activity and antiangiogenic effect, ocular and systemic disposition, and toxicity of digoxin in rabbits after intravitreal injection as a potential candidate for retinoblastoma treatment.METHODS:A panel of two ...
Abramson, David, Arana, Eloisa, Buitrago, Emiliano, Chantada, Guillermo Luis, Croxatto, Juan Oscar, del Sole, Maria Jose, Djaballah, Hakim, Francis, Jasmine, Laurent, Viviana Eunice, Mena, Hebe Agustina, Negrotto, Soledad, Schaiquevich, Paula Susana, Sgroi, Mariana, Winter, Ursula Andrea   +13 more
core   +2 more sources